Contrive Datum Insights has published "Ivermectin Market Size, Share & Industry Analysis, By Type (Injection, Powder, Others), Application (Cow, Sheep, Pig, Poultry, Others), End use (Veterinary and Animal Health, Human Health), Distribution channel (Veterinary Hospitals and Clinics, Retail Pharmacies and Agrovet Stores, Online Pharmacies, Direct and Institutional Sales), Product form (Active Pharmaceutical Ingredient (API), Formulated Products), and Regional Forecast, 2026-2034". The study sizes the global ivermectin market at USD 1.65 billion in 2025 and projects growth from USD 1.76 billion in 2026 to USD 3.03 billion by 2034, a compound annual growth rate of 7.03% across the forecast period.
Ivermectin is a macrocyclic lactone antiparasitic compound formulated as injections, oral solutions, tablets, pour-on liquids and premix powders to treat and prevent worm, mite and insect infestations in cattle, sheep, pigs, poultry and companion animals, and as an approved medicine for several human parasitic conditions including onchocerciasis, scabies and strongyloidiasis. Buyers span commercial livestock operations, veterinary hospitals and clinics, agrovet and retail pharmacy chains, animal health distributors, and human pharmaceutical wholesalers and public health procurement bodies. Formulations are supplied both as the active pharmaceutical ingredient to downstream manufacturers and as finished, ready-to-administer products sold directly to end users.
Rising livestock population and treatment demand in emerging economies
Rising livestock population and treatment demand in emerging economies is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7.03% a year, the type lines exposed to it move fastest: Powder compounds at 8.26%, taking its share of revenue from 29.82% to 33% and its value from USD 0.492 billion to USD 1 billion.
On the upside, the study's bull case assumes faster than expected livestock herd expansion in Asia Pacific and Latin America, combined with quicker uptake of premix and pour-on formulations, lifts volumes above the base case in every forecast year, which would take 2034 revenue to USD 3.44 billion rather than the USD 3.03 billion base case.
However, slower livestock herd growth, tighter residue and registration requirements in key export markets, and faster than expected rotation to alternative anthelmintics hold volumes below the base case in every forecast year, which would hold 2034 revenue to USD 2.66 billion. Injection, which carries 46.18% of 2025 revenue, already grows at only 6.15% against the market's 7.03%, so the largest part of the base is also its slowest.
Key Players Compete on Injection Volume and Powder Growth
Competition in the global ivermectin market runs along the type axis rather than the regional one. Injection holds 46.18% of 2025 revenue at USD 0.762 billion and remains the largest line through 2034 at 43%, making it the position hardest for a challenger to take. Powder, growing at 8.26%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 1.65 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Injection | 46.18% · USD 0.762 billion | — |
| Application | Cow | 37.98% · USD 0.627 billion | Poultry 9.68% |
| End use | Veterinary and Animal Health | 78% · USD 1.287 billion | Human Health 8.53% |
| Distribution channel | Retail Pharmacies and Agrovet Stores | 39.98% · USD 0.66 billion | Online Pharmacies 14.01% |
| Product form | Formulated Products | 70% · USD 1.155 billion | Active Pharmaceutical Ingredient (API) 7.76% |
- Based on regional analysis, Asia Pacific led the global ivermectin market in 2025 with 33.4% of global revenue at USD 0.551 billion, reaching USD 1.091 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 33.4% in 2025 to 36% in 2034, with revenue growing from USD 0.551 billion to USD 1.091 billion.
- Middle East and Africa remains the smallest region throughout, at 10.7% of 2025 revenue and 12% by 2034.
- Powder is projected to grow at 8.26% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 0.249 billion in 2025, 15.1% of global revenue.
The report segments the market across five axes; by type, and by application, end use, distribution channel and product form; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 2.66 billion and USD 3.44 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.